Bridgeway Capital Management’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-229,500
| Closed | -$143K | – | 1431 |
|
|
2020
Q4 | $143K | Sell |
229,500
-75,000
| -25% | -$46.3K | ﹤0.01% | 1241 |
|
|
2020
Q3 | $161K | Sell |
304,500
-50,000
| -14% | -$34K | ﹤0.01% | 1204 |
|
|
2020
Q2 | $243K | Buy |
354,500
+179,500
| +103% | +$142K | ﹤0.01% | 1097 |
|
|
2020
Q1 | $131K | Sell |
175,000
-35,000
| -17% | -$48.1K | ﹤0.01% | 1147 |
|
|
2019
Q4 | $317K | Hold |
210,000
| – | – | ﹤0.01% | 1102 |
|
|
2019
Q3 | $311K | Buy |
210,000
+70,000
| +50% | +$113K | ﹤0.01% | 1092 |
|
|
2019
Q2 | $181K | Hold |
140,000
| – | – | ﹤0.01% | 1195 |
|
|
2019
Q1 | $365K | Buy |
140,000
+125,000
| +833% | +$293K | ﹤0.01% | 1114 |
|
|
2018
Q4 | $25K | Sell |
15,000
-155,100
| -91% | -$435K | ﹤0.01% | 1354 |
|
|
2018
Q3 | $825K | Buy |
170,100
+50,000
| +42% | +$284K | 0.01% | 977 |
|
|
2018
Q2 | $751K | Sell |
120,100
-6,700
| -5% | -$49.9K | 0.01% | 995 |
|
|
2018
Q1 | $1.05M | Buy |
126,800
+65,000
| +105% | +$621K | 0.01% | 828 |
|
|
2017
Q4 | $630K | Buy |
61,800
+6,700
| +12% | +$64.3K | 0.01% | 1016 |
|
|
2017
Q3 | $504K | Hold |
55,100
| – | – | 0.01% | 1089 |
|
|
2017
Q2 | $402K | Sell |
55,100
-24,900
| -31% | -$188K | ﹤0.01% | 1147 |
|
|
2017
Q1 | $576K | Hold |
80,000
| – | – | 0.01% | 1026 |
|
|
2016
Q4 | $468K | Hold |
80,000
| – | – | 0.01% | 1113 |
|
|
2016
Q3 | $526K | Buy |
80,000
+15,000
| +23% | +$119K | 0.01% | 1079 |
|
|
2016
Q2 | $603K | Buy |
+65,000
| New | +$620K | 0.01% | 966 |
|
Bridgeway Capital Management's NEOS Position: Q1 2021 in Review
Bridgeway Capital Management sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 229,500 shares — an estimated $143K sold.
Bridgeway Capital Management first reported a position in NEOS in Q2 2016 and held it in 19 quarters. The position peaked at $1.05M in Q1 2018. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.
- Bridgeway Capital Management reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
- Bridgeway Capital Management sold 229,500 Neos Therapeutics, Inc shares in Q1 2021, an estimated $143K.
- Bridgeway Capital Management first reported a position in Neos Therapeutics, Inc in Q2 2016 and held it in 19 quarters.
- Bridgeway Capital Management's Neos Therapeutics, Inc position peaked at $1.05M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.
Based on Bridgeway Capital Management's 13F filing for Q1 2021, filed 17 May 2021.